Elm launched the Inner Dose Daily Skin Supplement to complement the serum. It’s meant to work from the inside out, tackling ...

Argo Biopharmaceutical Co., Ltd. (Argo Biopharma), a clinical-stage small interfering RNA (siRNA) therapeutics company, today announced that the National Medical Products Administration of China (NMPA ...

Vyvgart and robust R&D, balanced by risks and diversification potential. Read here for more analysis of ARGX stock.

Opinion - Real autonomy will come when states build prosperity through competition, innovation, and resilience.

Dianthus Therapeutics announces positive Phase II results for Claseprubart in myasthenia gravis, highlighting best-in-class potential.

Racial bias in appraisals is still a problem — but there are steps we can take to fight back. Philadelphia's reforms are a ...

Claseprubart 300mg and 600mg Q2W doses both achieved statistically significant and clinically meaningful improvements in Myasthenia Gravis ...

(Nasdaq: OMER) today announced the publication of a peer-reviewed manuscript in the American Journal of Hematology detailing survival outcomes in adult and pediatric patients with life-threatening ...

Federal funding pathways and how to position organizations to compete effectively. Alternative sources of capital to complement or bridge traditional federal opportunities.

In a landmark move, the US Food and Drug Administration (FDA) has given biotech company eGenesis the go-ahead to conduct a broader human trial in pig-to-human kidney transplants, marking a significant ...